Flow cytometric characterization of acute leukemia reveals a distinctive "blast gate" of murine T-lymphoblastic leukemia/lymphoma.

about

Flow cytometric characterization of acute leukemia reveals a distinctive "blast gate" of murine T-lymphoblastic leukemia/lymphoma.

Item

http://www.wikidata.org/entity/Q48507286

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Flow cytometric characterizati ...... mphoblastic leukemia/lymphoma.

@en

Flow cytometric characterizati ...... mphoblastic leukemia/lymphoma.

@nl

type

Item

label

Flow cytometric characterizati ...... mphoblastic leukemia/lymphoma.

@en

Flow cytometric characterizati ...... mphoblastic leukemia/lymphoma.

@nl

prefLabel

Flow cytometric characterizati ...... mphoblastic leukemia/lymphoma.

@en

Flow cytometric characterizati ...... mphoblastic leukemia/lymphoma.

@nl

P1476

Flow cytometric characterizati ...... mphoblastic leukemia/lymphoma.

@en

P2093

Arnold Ganser

http://www.w3.org/2001/XMLSchema#string

Guntram Büsche

http://www.w3.org/2001/XMLSchema#string

Kezhi Huang

http://www.w3.org/2001/XMLSchema#string

Min Yang

http://www.w3.org/2001/XMLSchema#string

Silke Glage

http://www.w3.org/2001/XMLSchema#string

Zengkai Pan

http://www.w3.org/2001/XMLSchema#string

Zhixiong Li

http://www.w3.org/2001/XMLSchema#string

P2860

High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol

CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling

Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers

Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia

Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model

FLT3 as a therapeutic target in AML: still challenging after all these years

Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.

Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation.

FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.

High-affinity neurotrophin receptors and ligands promote leukemogenesis.

P304

2320-2328

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.23410

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29416774

http://www.w3.org/2001/XMLSchema#string

P932

5788642

http://www.w3.org/2001/XMLSchema#string